Skip to content
lifestyle.latabloid.com/
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Jaguar Health, Inc.
Jaguar Health Satisfies Conditions for Receipt of Non-Dilutive $2 Million Holdback Payment from Future Pak for Commercial License to Mytesi and Canalevia-CA1
August 5, 2026
Jaguar Health Reports Positive Consumer and Veterinary Market Research Findings Supporting Commercial Opportunity for Neonorm Dog
July 28, 2026
Jaguar Health Regains Compliance with Nasdaq’s Publicly Held Shares Requirement and Receives Additional Extension, Until May 18, 2026, to Demonstrate Compliance with Nasdaq’s Bid Price Rule
May 22, 2026
Jaguar Health Announces Preliminary Discussion with FDA to Evaluate Breakthrough Therapy Designation for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)
May 21, 2026
Jaguar Health Expands Neonorm Franchise with Introduction of Neonorm Dog for Companion Animal Gut Health
May 21, 2026
Jaguar Health Announces Statistically Significant Results from Effectiveness Trial of Crofelemer (FDA Approved Canalevia-CA1) for Treatment of Chemotherapy-Induced Diarrhea in Dogs
May 20, 2026
Jaguar Health Granted Extension Until May 15, 2026, to Demonstrate Compliance with Nasdaq’s Bid Price Rule; Company Announces Reverse Stock Split
May 20, 2026
Jaguar Health Announces Acceptance of two Late-Breaking Abstracts for Liquid Oral Crofelemer Treatment of Intestinal Failure in Pediatric Patients at the European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN)
May 19, 2026
Jaguar Health Reports Approval of All Proposals at April 2026 Special Meeting of Stockholders
April 20, 2026
Artificial Intelligence (AI) Platforms Could Enhance Jaguar Health’s Development and Anticipated Commercialization of Crofelemer for Rare Disease Intestinal Failure (IF) Programs
April 13, 2026
←
Previous Page
1
2
3
Next Page
→